Avalo Therapeutics, Inc. (CERC) [Rocket]

Overview

Avalo Therapeutics, Inc. (CERC)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/05/2023	PRE 14A	Form PRE 14A - Other preliminary proxy statements:
10/03/2023	8-K	Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/14/2023	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
08/08/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/07/2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
08/07/2023	424B5	Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/03/2023	10-Q	Quarterly Report for the period ended June 30, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	0.0	6.7	6.8	7.0	28.4	1.2	0.0	0.0
Revenue growth	-100.0%	-0.8%	-4.0%	-75.3%	2367.4%
Cost of goods sold	0.0	0.3	-0.6	3.3	0.6	0.0	0.0	0.0
Gross profit	0.0	6.4	7.3	3.8	27.8	1.2	0.0	0.0
Gross margin		95.5%	108.4%	53.6%	97.8%	100.0%
Selling, general and administrative	0.0
Sales and marketing	0.0	2.3	1.5	0.5	0.6
Research and development		32.2	11.8	5.8	4.4	10.1	6.6	12.2
General and administrative	0.0	17.4	10.1	10.5	7.9	7.1	4.4	4.9
EBITA	1.5	-45.6	-16.1	-13.1	14.3	-16.1	-11.0	-17.1
EBITA margin		-680.0%	-237.8%	-186.2%	50.2%	-1394.6%
Amortization of intangibles	1.5	1.7	1.3	1.8	0.4
EBIT	0.0	-47.3	-17.4	-14.9	13.9	-16.1	-11.0	-17.1
EBIT margin		-706.0%	-257.7%	-212.1%	48.8%	-1394.6%
Pre-tax income	0.0	-70.0	-15.7	-35.4	13.8	-16.5	-10.5	-16.1
Income taxes	0.0	-2.8	0.3	0.0	2.0	0.0	0.0	0.0
Tax rate		4.0%		0.1%	14.2%	0.0%	0.0%	0.0%
Earnings from continuing ops		-67.2	-16.0	-30.5	7.8	-16.5	-10.5	-3.5
Earnings from discontinued ops				-4.8
Net income	0.0	-67.2	-16.0	-35.3	7.8	-16.5	-10.5	-3.5
Net margin		-1002.8%	-236.9%	-502.6%	27.3%	-1428.6%

Diluted EPS	$0.00	($0.99)	($0.35)	($0.88)	$0.41	($1.87)	($4.71)	($5.48)
Shares outstanding (diluted)	100.3	68.0	45.7	34.8	18.8	8.8	2.2	0.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.